Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $9.20 per share in its upcoming release, pointing to a year-over-year decline of 9.1%. It is anticipated that revenues will amount to $48.13 billion, exhibiting an increase of 11.4% compared to the year-ago quarter. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

But not this week. On Thursday, Elevance Health, the nation's second largest health insurer, will be the first health insurer out of the box to report second quarter earnings as rivals reel or recover from higher-than-expected medical costs. UnitedHealth isn't reporting its second quarter earnings until the end of the month. Much is at stake. The Elevance Health report comes after government-subsidized health insurance provider Centene withdrew its 2025 financial guidance earlier this month due to higher co ...

Core Viewpoint - A class action lawsuit has been filed against Elevance Health, Inc. for allegedly making false or misleading statements regarding the impact of Medicaid redetermination on the company's financial guidance and cost trends [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Elevance securities between April 18, 2024, and October 16, 2024, with a deadline for lead plaintiff applications set for July 11, 2025 [1]. - The defendants are accused of failing to disclose that the Medicaid redetermination process was leading to a significant rise in acuity and utilization of Medicaid members, contrary to their assurances to investors [3]. Financial Implications - Elevance's management claimed that premium rates negotiated with states were sufficient to manage the risks associated with Medicaid patients, despite rising Medicaid expenses [3]. - The lawsuit asserts that the financial guidance provided by Elevance did not accurately reflect the true impact of the redetermination process, leading to investor losses when the actual situation became known [3].

Core Viewpoint - Rosen Law Firm is reminding purchasers of Elevance Health, Inc. common stock about the lead plaintiff deadline for a class action lawsuit related to misleading statements made by the company during the Class Period from April 18, 2024, to October 16, 2024 [1][4]. Group 1: Class Action Details - Investors who purchased Elevance common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 11, 2025 [2]. - The lawsuit alleges that Elevance made false or misleading statements regarding the Medicaid redetermination process and its impact on the company's financial guidance [4]. Group 2: Allegations Against Elevance - The lawsuit claims that Elevance misrepresented its monitoring of cost trends associated with the Medicaid redetermination process, assuring investors that premium rates were sufficient to address risks [4]. - It is alleged that the acuity and utilization of Elevance's Medicaid members rose significantly, contrary to the company's assurances, leading to damages for investors when the truth was revealed [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors by stating they were monitoring cost trends related to Medicaid "redetermination" processes and that premium rates were sufficient to cover rising costs [4]. - Contrary to these claims, the redetermination process led to a significant increase in Medicaid member utilization, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - Following a Q3 2024 earnings report on October 17, 2024, where Elevance missed EPS expectations by $1.33 (13.7%) due to elevated medical costs, the company lowered its EPS guidance for 2024 from $37.20 to $33.00 (11.3%), causing the stock price to decline by $52.61 per share, or 10.6%, to a closing price of $444.35 [7][8].

Core Viewpoint - The market anticipates Elevance Health (ELV) will report a year-over-year decline in earnings despite higher revenues in its upcoming earnings report for the quarter ended June 2025 [1] Earnings Expectations - Elevance Health is expected to post quarterly earnings of $9.20 per share, reflecting a year-over-year decrease of 9.1% [3] - Revenues are projected to reach $48.13 billion, representing an increase of 11.4% compared to the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a stable outlook from covering analysts [4] - The Most Accurate Estimate for Elevance Health is lower than the Zacks Consensus Estimate, leading to an Earnings ESP of -5.05%, suggesting a bearish sentiment among analysts [12] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with positive readings being more reliable [9][10] - A positive Earnings ESP combined with a Zacks Rank of 1, 2, or 3 has shown a nearly 70% success rate in predicting earnings beats [10] Historical Performance - In the last reported quarter, Elevance Health exceeded expectations by delivering earnings of $11.97 per share against an expected $11.21, resulting in a surprise of +6.78% [13] - Over the past four quarters, the company has beaten consensus EPS estimates three times [14] Conclusion - While Elevance Health does not currently appear to be a strong candidate for an earnings beat, investors should consider other influencing factors when making investment decisions ahead of the earnings release [17]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits during the COVID-19 pandemic [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors who purchased Elevance common stock are encouraged to seek additional information and may have until July 11, 2025, to request to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused the review of Medicaid eligibility during COVID-19, which resumed in 2023, leading to increased scrutiny of Medicaid members [3]. Group 3: Financial Implications - Elevance claimed to be monitoring cost trends related to the Medicaid redetermination process and believed their negotiated rates were adequate [4]. - However, the redetermination process resulted in a significant increase in the acuity and utilization of Medicaid members, which was not reflected in Elevance's financial guidance for 2024 [5]. Group 4: Stock Performance - Following Elevance's announcement on July 17, 2024, regarding increased Medicaid utilization, the stock price fell by $32.21, or nearly 6%, from $553.14 to $520.93 per share [6]. - On October 17, 2024, Elevance reported Q3 2024 results, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business, leading to a further decline in stock price by $52.61, or nearly 11%, from $496.96 to $444.35 per share [7].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for the period between April 18, 2024, and October 16, 2024, due to financial disclosures that negatively impacted the company's stock price [1][5]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Financial Disclosures - On July 17, 2024, Elevance announced an expected increase in Medicaid utilization for the second half of the year, leading to a stock price decline of $32.21 per share, or 5.8%, closing at $520.93 [4]. - The company reported Q3 2024 financial results on October 17, 2024, missing EPS expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. EPS guidance for 2024 was lowered from $37.20 to $33.00, or 11.3% [5]. - Following the Q3 results, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by July 11, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its financial guidance [4] - It is claimed that the acuity and utilization of Elevance's Medicaid members increased significantly, contrary to the company's assurances to investors [4] - The misrepresentation of the Medicaid expenses and the impact on financial guidance led to investor damages when the true situation was revealed [4]

Core Viewpoint - A lawsuit has been filed against Elevance Health, Inc. and certain senior executives for potential violations of federal securities laws, specifically related to the management of Medicaid benefits and financial disclosures [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Indiana, captioned Miller v. Elevance Health, Inc., et al., No. 25-cv-0092 [2]. - Investors have until July 11, 2025, to request to be appointed to lead the case [2]. Group 2: Background on Medicaid Management - Elevance provides health insurance plans, including contracts with states to administer Medicaid benefits [3]. - The federal government paused Medicaid eligibility reviews during COVID, which resumed in 2023 [3]. Group 3: Allegations of Misrepresentation - Elevance claimed to be closely monitoring cost trends related to the Medicaid redetermination process and asserted that negotiated rates were adequate for the risk profiles of Medicaid patients [4]. - Contrary to these claims, the redetermination process led to a significant increase in the acuity and utilization of Elevance's Medicaid members, which was not reflected in the company's financial guidance for 2024 [5]. Group 4: Stock Price Impact - On July 17, 2024, Elevance announced an expectation of increased Medicaid utilization, resulting in a stock price decline of $32.21 per share, nearly 6%, from $553.14 to $520.93 [6]. - Following the Q3 2024 financial results announcement on October 17, 2024, which revealed a miss in EPS expectations by $1.33 (13.7%) due to elevated medical costs, the stock price fell by $52.61 per share, nearly 11%, from $496.96 to $444.35 [7].